One-dose “morning after” pill?
This article was originally published in The Tan Sheet
Executive Summary
HRA Pharma currently is conducting its own studies on one-dose levonorgestrel 1.5 mg drug for emergency contraception to be submitted to FDA in early 2004, the Paris-based firm says. HRA Pharma says it is not sure whether the NDA will be submitted for Rx or OTC status, but noted it likely would be difficult to switch OTC from Rx in light of FDA's recent "not approvable" letter to Barr Labs (1"The Tan Sheet" May 10, 2003, p. 5). Barr's current EC regimen includes two pills of levonorgestrel .75 mg taken 12 hours apart...
You may also be interested in...
Plan B OTC Submission Fails On Lack Of Data In Teens
Barr Labs will continue to work with FDA toward approval of emergency contraceptive Plan B (levonorgestrel .75 mg) for OTC use, the company said in a May 6 statement
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.